Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ok, understood.
I would guess that academic and clinical partners have some say in that. Also, I think the same concern (of statistical sufficiency) is operative here also: in other words, we might not have an "Oh my God we gave the patient a shot of cells and he jumped of the bed and started doing somersaults".
It may be that we'll end up with statically significant benefit, but just enough to get approval. I'll settle for that.
hi saud, we're definitely in the right places, congrats on AUPH, it's just a question of time. Hopefully Pluristem follows a similar path!
Hi hopester and FDA!
Thanks for continuing the good fight! I've been following the board very selectively (I'd run out of anti-emetic otherwise).
The fundamental reason for owning this company has not changed. They have deep and growing experience in a very hot and increasingly important area of medical advance. We've had enough positive data to warrant optimism and a commitment of money (that may vary per individual, but it's definitely my opinion)
We've had no failures in the clinic (that is known at this time), and they seem to be moving steadily forward. Yes, it takes time, that is not surprising at all, welcome to biotech investing.
The possibility of playing a role in taming the "cytokine storm" is very exciting (congrats to "Dr.Gary" for anticipating this!). There is pretty good evidence that it's possible, AND the fact that the cells are familiar to clinicians, AND that if it turns out to be effective, Pluristem can produce them en-masse. If it works out the notion of "game changer" is an understatement (both from a clinical and investment perspective).
Best to all,
zzaatt.
I've been following the board, it's been most edifying (as always).
Looking forward to data on covid-19 efficacy. Longer term we're chugging along toward what we can reasonably expect will be a positive outcome, irrespective of covid usefulness.
Greeting to old friends,
zzaatt.
[the beehive address is rejecting incoming (!!), hope she's happily buzzing about in safe Alpine fields with lovely flowers]
No need for special help from God!
Excellent P3 results and an unmet medical need, and further indications for $B+ markets (DES)!
This a temporary pause (although I would have expected it at a higher level), just need a bit of patience.
A reply worthy of his sobriquet ("sport", LOL)
BTW, I have not posted in a while, so:
Congratulations to those who had the faith and wisdom to stick with Aurinia, especially fellow Ariad alumni (and I join all in a special thanks to Vid!!).
Somebody called this company a gold mine. That seems about right! The indications following LN should add significant value, ... so my plan is to stick with the program, and hope for a very significant upside from here. Like Jesspro and others have said for months, this company has been low risk for a while, post-P3 this is true in spades.
Best to All,
zzaatt.
Thanks for your response! At this point I suppose it's just an academic exercise to speculate since we're getting the real answer very soon.
While yesterday was very nice, I don't give leaks much credence, on the other hand, hiring high level sales executives seems like a real good omen. I think it's fair to assume that the company knows what the data looks like.
The quality of the gadfly's posts on the Ariad board were about the same as his contributions here! Let's hope for a similar outcome!!
There seems to be a lot of noise on this line!